

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/73793 A3(51) International Patent Classification⁷: G01N 33/74,
33/68, G06F 17/50

Toronto, Ontario M5M 1Y8 (CA). OTTENSMEYER, Peter [CA/CA]; 27 Chatfield Drive, Don Mills, Ontario M3B 1K6 (CA). LUO, Robert, Z-T. [CA/US]; 4020-H Blue Bonnet Boulevard, Houston, TX 77025 (US).

(21) International Application Number: PCT/CA00/00605

(22) International Filing Date: 25 May 2000 (25.05.2000)

(74) Agent: DEETH WILLIAMS WALL LLP; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
2,273,576 27 May 1999 (27.05.1999) CA
09/461,791 15 December 1999 (15.12.1999) US
2,292,258 16 December 1999 (16.12.1999) CA(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/461,791 (CIP)
Filed on 15 December 1999 (15.12.1999)(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants and

(72) Inventors: YIP, Cecil [CA/CA]; 125 Melrose Avenue,

[Continued on next page]

(54) Title: IDENTIFICATION OF COMPOUNDS MODULATING INSULIN RECEPTOR ACTIVITY



(57) Abstract: The invention includes the fitted quaternary structure of insulin receptor. It also includes methods of identifying compounds that modulate insulin receptor activity by producing a compound that interacts with all or part of the fitted quaternary structure of insulin receptor or a fragment or derivative thereof and which thereby modulates insulin receptor activity.

WO 00/73793 A3